I agree that this site is using cookies. You can find further informations here.
X
Raine, T
1700  results:
Search for persons X
?
1

DOP64 Steroid-sparing effect of risankizumab vs ustekinumab..:

Raine, T ; Danese, S ; Schreiber, S...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i190-i190 , 2024
Link: https://doi.org/10.1093/..
 
?
2

P1038 Does combination immunomodulator therapy impact real-..:

Desoki, R ; Kapizioni, C ; Lam, D...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1873-i1873 , 2024
Link: https://doi.org/10.1093/..
 
?
3

P045 MMP12 stimulates colonic afferents, and nociceptors th..:

Gupta, R ; Higham, J ; Raine, T..
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i307-i307 , 2024
Link: https://doi.org/10.1093/..
 
?
4

OP01 PROFILE: a multi-centre, randomised, open-label, bioma..:

Noor, N ; Lee, J ; Bond, S...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1-i2 , 2024
Link: https://doi.org/10.1093/..
 
?
5

P711 Outcomes of Outpatient Biologic Exposed Patients Hospi..:

Al-Bawardy, B ; Al Sulais, E ; Mukhtar, M..
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1341-i1341 , 2024
Link: https://doi.org/10.1093/..
 
?
6

P668 Differential efficacy of biologic agents for Inflammat..:

Kapizioni, C ; Desoki, R ; Balendran, K...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i800-i801 , 2023
Link: https://doi.org/10.1093/..
 
?
7

P273 Severity of colitis and clinical outcomes for patients..:

Al Sulais, E ; Mukhtar, M S H ; Parkes, G..
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i423-i424 , 2023
Link: https://doi.org/10.1093/..
 
?
8

P778 Effectiveness and safety of a second-line rescue thera..:

García, M J ; Riestra, S ; Amiot, A...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i911-i912 , 2023
Link: https://doi.org/10.1093/..
 
?
9

An innovative method to identify educational need regarding..:

Rosembert, D ; Eldridge, F ; Raine, T.
International Journal of Pharmacy Practice.  31 (2023)  Supplement_2 - p. ii47-ii48 , 2023
Link: https://doi.org/10.1093/..
 
?
10

OP33 Results of a randomised controlled trial to evaluate I..:

Raine, T ; Vaja, S ; Subramanian, S...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i43-i46 , 2023
Link: https://doi.org/10.1093/..
 
?
11

P488 Trends in corticosteroid (CS) use over time and follow..:

Raine, T ; Melmed, G Y ; Finney-Hayward, T...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i454-i455 , 2022
Link: https://doi.org/10.1093/..
 
?
12

P554 Vedolizumab Associated quality of Life and inflammator..:

Lim, S ; Gros Alcade, B ; Lehmann, A...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i499-i500 , 2022
Link: https://doi.org/10.1093/..
 
?
13

OP14 Interpreting genome-wide association studies of Inflam..:

Krzak, M ; Taylor, L ; Alegbe, T...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i014-i015 , 2022
Link: https://doi.org/10.1093/..
 
?
14

DOP74 Comparative effectiveness of vedolizumab and ustekinu..:

Desoki, R ; Balendran, K ; Kapizioni, C...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i117-i118 , 2022
Link: https://doi.org/10.1093/..
 
?
15

DOP09 Phenotypic and genetic determinants of medication res..:

Zhang, Q ; Fachal, L ; Shawky, R...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i058-i059 , 2022
Link: https://doi.org/10.1093/..
 
1-15